Allworth Financial LP Neurocrine Biosciences Inc Transaction History

Allworth Financial LP

$17.3 Billion
Q4 2024

A detailed history of Allworth Financial LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Allworth Financial LP holds 166 shares of NBIX stock, worth $20,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166

Previous 136 22.06%

Holding current value

$20,034

Previous $15,000 46.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$111.62 - $139.44 $3,348 - $4,183	30 Added 22.06%	166 $22,000
Q3 2024 Oct 23, 2024	SELL	$114.58 - $153.15 $11,228 - $15,008	-98 Reduced 41.88%	136 $15,000
Q2 2024 Jul 23, 2024	BUY	$130.86 - $143.19 $19,105 - $20,905	146 Added 165.91%	234 $32,000
Q4 2023 Jan 24, 2024	BUY	$106.07 - $132.76 $3,394 - $4,248	32 Added 57.14%	88 $11,000
Q3 2023 Oct 31, 2023	SELL	$94.02 - $117.1 $1,786 - $2,224	-19 Reduced 25.33%	56 $6,000
Q2 2023 Jul 18, 2023	SELL	$89.53 - $104.87 $179 - $209	-2 Reduced 2.6%	75 $7,000
Q1 2023 Apr 18, 2023	BUY	$94.11 - $123.02 $2,352 - $3,075	25 Added 48.08%	77 $7,000
Q4 2022 Jan 13, 2023	SELL	$106.72 - $127.06 $106 - $127	-1 Reduced 1.89%	52 $0
Q3 2022 Oct 18, 2022	BUY	$92.03 - $107.81 $2,300 - $2,695	25 Added 89.29%	53 $6,000
Q2 2022 Jul 13, 2022	BUY	$75.79 - $100.07 $682 - $900	9 Added 47.37%	28 $3,000
Q1 2022 Apr 22, 2022	SELL	$72.45 - $94.81 $6,375 - $8,343	-88 Reduced 82.24%	19 $2,000
Q4 2021 Jan 21, 2022	SELL	$79.65 - $106.22 $1,354 - $1,805	-17 Reduced 13.71%	107 $9,000
Q3 2021 Nov 02, 2021	BUY	$86.18 - $99.03 $10,686 - $12,279	124 New	124 $12,000

Others Institutions Holding NBIX

# of Institutions

654

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.

Account

Allworth Financial LP Neurocrine Biosciences Inc Transaction History